Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 7/20 | 0.61 |
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | CNR1 | P21554 | 4/20 | 0.59 |
| ▸ | CNR2 | P34972 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16903055 | 0.96 | TP53 (0.63) | THRBTP53MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL19157334 | 0.96 | THRB (0.60) | THRBTP53MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL16838146 | 0.94 | THRB (0.57) | THRBTP53MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL18085481 | 0.91 | TP53 (0.65) | THRBTP53MAPTSMN1; SMN2CNR1 | |
| SCHEMBL15076711 | 0.90 | CYP3A4 (0.67) | TP53MAPTSMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL19157129 | 0.90 | CYP3A4 (0.62) | THRBTP53MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL15076488 | 0.88 | CYP3A4 (0.62) | TP53MAPTSMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL18085485 | 0.88 | TP53 (0.78) | TP53MAPTSMN1; SMN2CNR1CNR2 | |
| SCHEMBL21623242 | 0.88 | CYP3A4 (0.59) | THRBTP53MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL21623329 | 0.88 | CYP3A4 (0.70) | THRBTP53MAPTSMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030869-B2 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | ASSEMBLY BIOSCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11814376-B2 | Hepatitis b core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230183213-A1 | 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | ASSEMBLY BIOSCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| WO-2020255012-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND CAPSID ASSEMBLY MODULATORS BEING SULFONAMIDE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | disclosed |
| US-10632112-B2 | Combination therapy for treatment of HBV infections | NOVIRA THERAPEUTICS, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| EP-3312160-B1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20190209541-A1 | COMBINATION THERAPY FOR TREATMENT OF HBV INFECTIONS | NOVIRA THERAPEUTICS INC. | 2019-07-11 | — | — | US | disclosed |
| US-10196376-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| EP-3312160-A1 | HEPATITIS B ANTIVIRAL AGENTS | Novira Therapeutics Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| US-9061008-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150152073-A1 | Hepatitis B Antiviral Agents | NOVIRA THERAPEUTICS, INC. | 2015-06-04 | — | — | US | disclosed |
| US-20150152073-A1 | Hepatitis B Antiviral Agents | NOVIRA THERAPEUTICS, INC. | 2015-06-04 | — | — | US | disclosed |
| US-20140178337-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. | 2014-06-26 | — | — | US | disclosed |
| US-20140178337-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. | 2014-06-26 | — | — | US | disclosed |
| US-8629274-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629274-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20130251673-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130251673-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2013096744-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10632112-B2 | Combination therapy for treatment of HBV infections | IFNAR1, IFNG, HDGF | THRB 1299/4885TP53 920/4885MAPT 3999/4885 |
| US-20150152073-A1 | Hepatitis B Antiviral Agents | HAVCR2, EIF2AK2, IRF3 | THRB 2689/4885TP53 1486/4885MAPT 4607/4885 |
| US-20230183213-A1 | 5-MEMBERED HETEROARYL CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV | HCCS, HAVCR2, MAVS | THRB 2219/4885TP53 65/4885MAPT 3215/4885 |
| US-20140178337-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, EIF2AK2, IRF3 | THRB 2689/4885TP53 1486/4885MAPT 4607/4885 |
| US-10196376-B2 | Hepatitis B antiviral agents | HAVCR2, EIF2AK2, IRF3 | THRB 2689/4885TP53 1486/4885MAPT 4607/4885 |
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | THRB 1373/4885TP53 411/4885MAPT 2896/4885 |
| US-20190209541-A1 | COMBINATION THERAPY FOR TREATMENT OF HBV INFECTIONS | IFNAR1, IFNG, HDGF | THRB 1299/4885TP53 920/4885MAPT 3999/4885 |
| US-11814376-B2 | Hepatitis b core protein modulators | HAVCR2, FABP1, MAVS | THRB 1373/4885TP53 411/4885MAPT 2896/4885 |
| US-20130251673-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, EIF2AK2, IRF3 | THRB 2689/4885TP53 1486/4885MAPT 4607/4885 |
| US-12030869-B2 | 5-membered heteroaryl carboxamide compounds for treatment of HBV | HCCS, HAVCR2, MAVS | THRB 2219/4885TP53 65/4885MAPT 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.